Literature DB >> 20349407

Effect of phlorizin on SGLT2 expression in the kidney of diabetic rats.

Horacio Osorio1, Rocío Bautista, Amelia Rios, Martha Franco, Abraham Arellano, Hilda Vargas-Robles, Eunice Romo, Bruno Escalante.   

Abstract

BACKGROUND: The purpose of our study was to determine whether increased SGLT2 expression in the kidney of diabetic rats was associated with the development of hypertension and to investigate the effect of phlorizin (P) on blood pressure and SGLT2 expression in diabetic rats.
METHODS: The animals were divided into two groups: Control (C) and streptozotocin-induced diabetic (D) rats were used to evaluate SGLT2 activity in brush border membrane vesicles (BBMV) using a rapid filtration technique. Others animals were divided into two groups: Normal (NSD) or high salt diet (4%)(HSD), and subdivided in four groups: C, C+P, D, D+P. Systolic blood pressure (SBP) was recorded for 30 days by the use of a telemetric system and at day 30 urine samples (24 h) were collected to evaluate renal function and SGLT2 expression in the renal cortex.
RESULTS: At day 30, diabetic animals with NSD or HSD exhibited hyperglycemia, lower body weight, glycosuria, diuresis, decrease natriuresis, increased SBP values and SGLT2 expression. In diabetic rats, phlorizin treatment decreased hyperglycemia and prevented development of hypertension, decreased SGLT2 activity in BBMV but did not modify SGLT2 expression.
CONCLUSIONS: In conclusion, SGLT2 inhibition prevented the development of hypertension in diabetic rats as well as hyperglycemia, suggesting a hypertensive mechanism associated with SGLT2 activity and the likelihood that increased SGLT2 expression may be associated with progression of diabetic renal complications.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20349407

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  15 in total

Review 1.  SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.

Authors:  Ele Ferrannini; Anna Solini
Journal:  Nat Rev Endocrinol       Date:  2012-02-07       Impact factor: 43.330

2.  Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule.

Authors:  Thaissa Dantas Pessoa; Luciene Cristina Gastalho Campos; Luciene Carraro-Lacroix; Adriana C C Girardi; Gerhard Malnic
Journal:  J Am Soc Nephrol       Date:  2014-03-20       Impact factor: 10.121

3.  Enhanced oral bioavailability and anti-diabetic activity of canagliflozin through a spray dried lipid based oral delivery: a novel paradigm.

Authors:  Dilpreet Singh; Amrit Pal Singh; Drishtant Singh; Anup Kumar Kesavan; Saroj Arora; Ashok K Tiwary; Neena Bedi
Journal:  Daru       Date:  2020-02-07       Impact factor: 3.117

Review 4.  Paving the way towards effective plant-based inhibitors of hyaluronidase and tyrosinase: a critical review on a structure-activity relationship.

Authors:  Jakub Gębalski; Filip Graczyk; Daniel Załuski
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

Review 5.  Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models.

Authors:  Sandra Feijóo-Bandín; Alana Aragón-Herrera; Manuel Otero-Santiago; Laura Anido-Varela; Sandra Moraña-Fernández; Estefanía Tarazón; Esther Roselló-Lletí; Manuel Portolés; Oreste Gualillo; José Ramón González-Juanatey; Francisca Lago
Journal:  Int J Mol Sci       Date:  2022-05-18       Impact factor: 6.208

6.  Intestinal electrogenic sodium-dependent glucose absorption in tilapia and trout reveal species differences in SLC5A-associated kinetic segmental segregation.

Authors:  Marina Subramaniam; Lynn P Weber; Matthew E Loewen
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-01-02       Impact factor: 3.619

7.  Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.

Authors:  T Nagata; T Fukuzawa; M Takeda; M Fukazawa; T Mori; T Nihei; K Honda; Y Suzuki; Y Kawabe
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

8.  Angiotensin receptor blocker telmisartan suppresses renal gluconeogenesis during starvation.

Authors:  Akihiro Tojo; Saaya Hatakeyama; Satoshi Kinugasa; Masaomi Nangaku
Journal:  Diabetes Metab Syndr Obes       Date:  2015-02-13       Impact factor: 3.168

9.  Sodium-glucose cotransporter inhibition prevents oxidative stress in the kidney of diabetic rats.

Authors:  Horacio Osorio; Israel Coronel; Abraham Arellano; Ursino Pacheco; Rocío Bautista; Martha Franco; Bruno Escalante
Journal:  Oxid Med Cell Longev       Date:  2012-11-20       Impact factor: 6.543

10.  Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus.

Authors:  Timothy P Reilly; Michael J Graziano; Evan B Janovitz; Thomas E Dorr; Craig Fairchild; Francis Lee; Jian Chen; Tai Wong; Jean M Whaley; Mark Tirmenstein
Journal:  Diabetes Ther       Date:  2014-01-29       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.